All deliverables
Digital · Media, investors & public

Press Release.
The announcement, structured for the audience that matters.

Audience
Media, investors & public
Format
500–800 word formatted release
Style
AP style, boilerplate
Price from
£180
What's produced

A complete, formatted press release ready for distribution.

The Spectrum& Press Release is a 500–800 word formatted news release in AP style, complete with dateline, headline, boilerplate, and media contact block. Simple tier covers product and service announcements. Medium tier adds data announcement structure with correct trial citation. Complex tier handles major Phase III readouts with KOL quotes, trial background, and media backgrounder.

Ink writes the copy. Medi is added at medium and complex tiers to ensure clinical data is accurately cited and correctly framed. Aria sources the supporting evidence at complex tier. Press releases are not subject to ABPI promotional code review, but factual accuracy is verified against source.

The output is a Word/PDF-formatted release at the correct layout standard, ready to distribute to your PR team or wire service. Boilerplate text for your company is generated if not supplied.

The team

The team behind it.

Core team shown. Complexity tier determines which additional specialists are activated.

SY
Sys
Head of Systems
IN
Ink
Copywriter
PA
Pace
Project Manager
ME
Medi
Medical Writer
AR
Aria
Research Analyst
Complexity tiers

Simple, Medium, or Complex — you choose the depth.

Simple Medium Complex
Scope Product/service announcement Data announcement with trial reference Major trial readout + KOL quotes + backgrounder
Team Sys, Ink, Pace + Medi + Aria
Price range ~£180 ~£340 ~£680
Best for Approval news, partnership, milestone Congress data presentation, interim readout Phase III topline, regulatory submission, major label update
Example output

What it looks like.

Press Release (Simple) — formatted output
FOR IMMEDIATE RELEASE
Hartwell Pharmaceuticals Announces UK Approval of Verixtol® (verixtumab 150mg) for Moderate-to-Severe Plaque Psoriasis
London, UK — March 2026
Hartwell Pharmaceuticals today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Verixtol® (verixtumab 150mg), a selective interleukin-17A (IL-17A) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
"This approval represents a significant step forward for patients with moderate-to-severe plaque psoriasis in the UK," said [CEO Name], Chief Executive Officer of Hartwell Pharmaceuticals. "We are committed to ensuring rapid access for the patients who need it."
About Hartwell Pharmaceuticals
Hartwell Pharmaceuticals is a UK-based biopharmaceutical company focused on immunology and rare disease. Founded in 2014, the company has a portfolio of five approved medicines across dermatology and rheumatology.
Media contact: press@hartwellpharma.com · +44 20 7946 0123
Not applicable — Press releases are not ABPI-regulated internal documents Spectrum& — spectrumand.com
Press Release (Medium) — conference data announcement
FOR IMMEDIATE RELEASE
Hartwell Pharmaceuticals Presents Full VERIFY-1 52-Week Data at EADV Congress 2026, Confirming Durable Response with Verixtol®
Amsterdam, Netherlands — March 2026
Hartwell Pharmaceuticals today presented 52-week data from the VERIFY-1 Phase III trial of Verixtol® (verixtumab 150mg) at the European Academy of Dermatology and Venereology (EADV) annual congress. The data demonstrate that PASI 90 response rates were maintained through week 52, with 69% of patients achieving PASI 90 at this timepoint compared to 72% at week 16.
69%
PASI 90 maintained at week 52 (n=312, per-protocol population)1
1. VERIFY-1 52-week data. EADV Annual Congress, Amsterdam. March 2026.
Not applicable — Press releases are not ABPI-regulated Spectrum& — spectrumand.com
Press Release (Complex) — Phase III readout
FOR IMMEDIATE RELEASE
VERIFY-AXIA Phase III Trial Meets Primary Endpoint: Verixtol® Demonstrates Significant Improvement in ASAS40 Response in Active Axial Spondyloarthritis
London, UK — March 2026
Hartwell Pharmaceuticals today announced positive top-line results from the VERIFY-AXIA Phase III randomised controlled trial evaluating Verixtol® (verixtumab 150mg) in adults with active axial spondyloarthritis (axSpA), including both radiographic (r-axSpA) and non-radiographic (nr-axSpA) subtypes.
The trial met its primary endpoint, with 58% of patients in the verixtumab 150mg group achieving ASAS40 response at week 16, compared to 17% in the placebo group (p<0.0001, n=341). Statistically significant improvements were observed across all key secondary endpoints, including ASDAS-ID, BASDAI50, and MRI inflammation scores.
"These results establish verixtumab as a potential new treatment option for patients with active axSpA, including those who have inadequate responses to NSAIDs or prior biologics," said Professor [Name], Principal Investigator of VERIFY-AXIA and Professor of Rheumatology at [University].
Media contact: press@hartwellpharma.com · Investor relations: ir@hartwellpharma.com
Not applicable — Press releases are not ABPI-regulated Spectrum& — spectrumand.com

Full rendered examples will be available at launch.

Start your Press Release.

Tell us about your brief. We'll assemble the right team and get started today.

Start a project →